MedPath

Effect of Vitamin D Therapy in Autism Spectrum Disorder

Phase 1
Recruiting
Conditions
Effect of Drug
Interventions
Other: Habilitation
Registration Number
NCT05595044
Lead Sponsor
Mansoura University
Brief Summary

The aim of this work is to study the adjuvant effect of vitamin D supplementation on inflammatory marker (IL4) and habilitation outcome in children with Autism Spectrum Disorder in order to evaluate its efficiency as a treatment option based on correction of immune dysfunction.

Detailed Description

Vitamin D is one of environmental factors potentially modulating brain development and functioning. Vitamin D3 deficiency during pregnancy and early childhood is suggested to be one of several risk factors for development of ASD in genetically predisposed individuals (Cies´lin´ska et al., 2017). Many studies e.g (Eyles et al., 2013; Grant and Sole, 2009; Noriega and Savelkoul, 2014) suggested that vitamin D has an important role as a neuroactive steroid, which can affect neuronal differentiation, axonal connectivity and brain structure and function. Vitamin D has been increasingly recognized for its immunomodulatory role and has been implicated in the pathogenesis of autoimmune disorders. Also it has numerous and dynamic effects on the immune system, ranging from altering T cell responses and regulating cytokine pathways (Kocˇovská et al., 2017). So from this point of view, this study will be conducted to show adjuvant effect of vitamin D supplementation on ASD children at clinical level and inflammatory marker (IL4).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  1. Delayed language development due to ASD.
  2. Good nutritional status (Normal weight and height using growth charts, no Anemia and no clinical evidence of vitamin deficiency).
  3. Normal hearing and vision.
Exclusion Criteria
  1. History of vitamin D supplementation, drugs modulating immune system as steroid and drug formula containing vitamin D as cod liver oil.
  2. Known chronic disease.
  3. Known neurological disorders or psychiatric disorders.
  4. Known autoimmune or gastrointestinal disorders.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HabilitationHabilitation40 ASD children receiving habilitation
Vitamin D therapy and habilitationVitamin D40 ASD children receiving Vitamin D therapy and habilitation
Vitamin D therapy and habilitationHabilitation40 ASD children receiving Vitamin D therapy and habilitation
Primary Outcome Measures
NameTimeMethod
Serum vitamin D6 weeks

Assessment of serum vitamin D by ADVIA Centaur® Vitamin D Total (VitD) assay

language ability test4 months

language test for assessment of language age

Inflammatory marker4 months

Assessment of serum interleukin 4 by ELISA technique

CARS questionnaire for assessment of ASD severity4 months

CARS questionnaire for assessment of ASD severity

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mansoura university hospital

🇪🇬

Mansoura, Egypt

© Copyright 2025. All Rights Reserved by MedPath